5:15 PM
 | 
Nov 09, 2009
 |  BC Extra  |  Top Story

Enzon to sell specialty pharma business

Sigma-Tau S.p.A. (Rome, Italy) will acquire the specialty pharmaceuticals business of Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) for $300 million in cash and up to $27 million in potential milestones. The deal includes four marketed products: antifungal Abelcet...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >